ASH 2023 | TOP-FLOR: treatment of newly-diagnosed FL with golcadomide, rituximab +/- nivolumab
Eliza Hawkes, FRACP, MD, MBBS, The Olivia Newton-John Cancer Wellness & Research Centre at Austin Health, Melbourne, Australia, introduces the TOP-FLOR trial (NCT05788081), an open-label, multicenter Phase II trial which will randomize up to 40 eligible patients with follicular lymphoma (FL) to receive rituximab, golcadomide (BMS986369) +/- nivolumab for a fixed 8-month duration. The study aims to investigate the complete response (CR) rate, overall toxicity, time to treatment failure (TTF), progression-free survival (PFS) and overall survival (OS). Dr Hawkes hopes that golcadomide, a novel cereblon-modulating (CELMoD) compound, will be less toxic and more potent in patients with FL than the current standard of care. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Board of Directors/Advisory Committee: Novartis, Janssen, Merck Sharpe & Dohme, Gilead, Astra Zeneca, Roche, Bristol-Myers Squibb
Travel Expenses: Astra Zeneca, Antengene, Specialised Therapeutics
Speakers Bureau: Janssen, Astra Zeneca, Regeneron
Research Funding: Astra Zeneca, Merck KgA, Roche, Bristol-Myers Squibb
Honoraria: Specialised Therapeutics
Other: Novartis, Beigene
